Nothing Special   »   [go: up one dir, main page]

AU2002360774A8 - 4-substituted fused heteropyrimidines and fused hetero-4-pyrimidones - Google Patents

4-substituted fused heteropyrimidines and fused hetero-4-pyrimidones

Info

Publication number
AU2002360774A8
AU2002360774A8 AU2002360774A AU2002360774A AU2002360774A8 AU 2002360774 A8 AU2002360774 A8 AU 2002360774A8 AU 2002360774 A AU2002360774 A AU 2002360774A AU 2002360774 A AU2002360774 A AU 2002360774A AU 2002360774 A8 AU2002360774 A8 AU 2002360774A8
Authority
AU
Australia
Prior art keywords
fused
heteropyrimidines
pyrimidones
hetero
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002360774A
Other versions
AU2002360774A1 (en
Inventor
Donald E Bierer
William J Scott
Andreas Stolle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Bayer Corp
Original Assignee
Bayer AG
Bayer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer AG, Bayer Corp filed Critical Bayer AG
Publication of AU2002360774A1 publication Critical patent/AU2002360774A1/en
Publication of AU2002360774A8 publication Critical patent/AU2002360774A8/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2002360774A 2001-12-28 2002-12-27 4-substituted fused heteropyrimidines and fused hetero-4-pyrimidones Abandoned AU2002360774A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34415501P 2001-12-28 2001-12-28
US60/344,155 2001-12-28
PCT/US2002/041428 WO2003057149A2 (en) 2001-12-28 2002-12-27 4-substituted fused heteropyrimidines and fused hetero-4-pyrimidones

Publications (2)

Publication Number Publication Date
AU2002360774A1 AU2002360774A1 (en) 2003-07-24
AU2002360774A8 true AU2002360774A8 (en) 2003-07-24

Family

ID=23349286

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002360774A Abandoned AU2002360774A1 (en) 2001-12-28 2002-12-27 4-substituted fused heteropyrimidines and fused hetero-4-pyrimidones

Country Status (2)

Country Link
AU (1) AU2002360774A1 (en)
WO (1) WO2003057149A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1651652B1 (en) 2003-07-24 2006-12-27 Bayer Pharmaceuticals Corporation Substituted tetrahydrobenzothienopyrimidinamine compounds useful for treating hyper-proliferative disorders
US8637528B2 (en) 2007-03-27 2014-01-28 Omeros Corporation Use of PDE7 inhibitors for the treatment of movement disorders
MX2009010450A (en) 2007-03-27 2009-11-23 Omeros Corp The use of pde7 inhibitors for the treatment of movement disorders.
US8802849B2 (en) 2008-02-19 2014-08-12 Vichem Chemie Kutató Kft. Tricyclic benzo[4,5]thieno-[2,3-d]pyrimidine-4-yl-amin derivatives, their salts, process for producing the compounds and their pharmaceutical use
WO2012064667A2 (en) 2010-11-08 2012-05-18 Omeros Corporation Treatment of addiction and impulse-control disorders using pde7 inhibitors
US9220715B2 (en) 2010-11-08 2015-12-29 Omeros Corporation Treatment of addiction and impulse-control disorders using PDE7 inhibitors
EP2663312B1 (en) 2011-01-10 2017-10-11 Nimbus Iris, Inc. Irak inhibitors and uses thereof
BR112013023266B8 (en) 2011-03-15 2021-04-06 L Livermore Nat Security Llc tricyclic gyrase inhibitors
JP6126131B2 (en) 2012-01-10 2017-05-10 ニンバス アイリス， インコーポレイテッド IRAK inhibitors and uses thereof
EP2872144A4 (en) * 2012-07-11 2015-12-02 Nimbus Iris Inc Irak inhibitors and uses thereof
BR112015000561A2 (en) 2012-07-11 2017-06-27 Nimbus Iris Inc irak inhibitors and uses thereof
AU2013312477B2 (en) * 2012-09-06 2018-05-31 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
JP2016505012A (en) 2013-01-10 2016-02-18 ニンバス アイリス， インコーポレイテッド IRAK inhibitors and uses thereof
CA2925211A1 (en) 2013-09-27 2015-04-02 Nimbus Iris, Inc. Irak inhibitors and uses thereof
AU2023260728A1 (en) * 2022-04-28 2024-10-10 Enanta Pharmaceuticals, Inc. Pyrimidinone-containing 17-beta-hydroxysteroid dehydrogenase type 13 inhibitors
WO2024038089A1 (en) 2022-08-18 2024-02-22 Mitodicure Gmbh Use of a therapeutic agent with phosphodiesterase-7 inhibitory activity for the treatment and prevention of diseases associated with chronic fatigue, exhaustion and/or exertional intolerance

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5654307A (en) * 1994-01-25 1997-08-05 Warner-Lambert Company Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
NZ312665A (en) * 1995-07-06 1999-08-30 Novartis Ag Rrolopyrimidines(7h-pyrrolo[2,3-d]pyrimidine and preparation of these

Also Published As

Publication number Publication date
WO2003057149A3 (en) 2003-12-18
WO2003057149A2 (en) 2003-07-17
WO2003057149B1 (en) 2004-02-19
AU2002360774A1 (en) 2003-07-24

Similar Documents

Publication Publication Date Title
EP1463742A4 (en) Novel pyrazolo-and pyrrolo-pyrimidines and uses thereof
HUP0500989A2 (en) Animicrobial polypeptides and their uses
EP1408971A4 (en) Novel quinolines and uses thereof
EP1408978A4 (en) Novel phenylamino-pyrimidines and uses thereof
GB2391571B (en) Sintered wellscreen
AU2002360774A8 (en) 4-substituted fused heteropyrimidines and fused hetero-4-pyrimidones
GB0104206D0 (en) Radiometers
EP1434772A4 (en) Compounds and methods
IL154553A0 (en) Urocortin-iii and uses thereof
AU2002357891A8 (en) Dtat fusion toxin
AU2002359694A8 (en) Compounds and methods
GB0127696D0 (en) Antifuses
EP1392317A4 (en) Substituted 1-benzazepines and derivatives thereof
GB2400319B (en) Cannabinoid-rich extracts
EP1408985A4 (en) Novel pyridopyrimidones and uses thereof
AU2001290641A1 (en) Substituted fused pyrroleimines and pyrazoleimines
HUP0401162A3 (en) Substituted c-furan-2-yl-methylamine and c-thiophen-2-yl-methylamine derivatives
EP1379240A4 (en) Compounds and methods
EP1367123A4 (en) Neurotonin and use thereof
EP1468076A4 (en) Defective entities and uses therefor
HUP0202901A2 (en) Modified based metathese-catalyzers
GB0118984D0 (en) Fusion of cells
TW545691U (en) Improved fuse structure
GB0103997D0 (en) Joint
AU147289S (en) Fuse

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase